Cost-effectiveness of lutetium ((177)Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden

por Palmer, Jayne, Leeuwenkamp, Oscar R
Publicado 2020

Use of [(177)Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study

por Glover, Matthew, Caplin, Martyn, Leeuwenkamp, Oscar R., Longworth, Louise
Publicado 2021

Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review

por Watson, Catherine, Tallentire, Craig William, Ramage, John K, Srirajaskanthan, Rajaventhan, Leeuwenkamp, Oscar R, Fountain, Donna
Publicado 2020

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE

por Strosberg, Jonathan R., Srirajaskanthan, Rajaventhan, El-Haddad, Ghassan, Wolin, Edward M., Chasen, Beth A., Kulke, Matthew H., Bushnell, David L., Caplin, Martyn E., Baum, Richard P., Hendifar, Andrew E., Öberg, Kjell, Ruszniewski, Philippe, Santoro, Paola, Broberg, Per, Leeuwenkamp, Oscar R., Krenning, Eric P.
Publicado 2021